logo-loader

Plus8 Global Ventures hires Merriman Capital as financial advisor

Published: 09:59 27 Sep 2013 EDT

no_picture_pai

Plus8 Global Ventures (CNSX:PGT) says it has hired San Francisco-based investment bank Merriman Capital as a financial advisor to assisst with the financial tech company's capital market strategies and investor development opportunities. 

“As the role of social collaboration has become an increasingly powerful force in investing, we feel there is an enormous opportunity to consolidate and innovate,” said the company’s founder and CEO, David Elias. 

“Merriman will be a strong partner as we execute our strategy of growth via expansion and acquisition in order to become a leading firm in the social investing space.”

Plus8 offers financial products and services that provide real-time collaboration and social connectivity among investors. Currently, the company is focused on launching Its Trader|OS communication platform, which allows independent traders to exchange and validate ideas instantly, while offering revenue-generating solutions to premium content publishers. 

It also allows users to customize their layout, including the ability to launch a video to watch financial news, and lets traders follow and connect with other users, aggregate content, and share all this information, both on the platform and across their personal networks.

The company, which bills its product as the 'next generation of investor tools', is led by Elias, who began his career on the floors of the Comex and CBOT before trading derivatives at Bear Stearns. He then went on to start one of the first social marketing agencies,  which was later acquired by the UK’s largest privately-owned communications group.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 2 minutes ago